Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1418, 2003-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :
Access to resources
Recommend
PEG IFN- -2b + ribavirin superior for HCV + HIV infection
Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. :
PEG IFN- -2b + ribavirin: 24 weeks sufficient for HCV-2 and HCV-3?
Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. :
PEG IFN- -2b + weight-based ribavirin best value in hep C
Inpharma, Vol. 1, Iss. 1386, 2003-01 ,pp. :
PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :